20628-07-3

Usage

Preparation

Preparation by reaction of acetic acid with 4-methylanisole in the presence of trifluoromethyl-sulfonic anhydride (Tf2O) for 3 min at r.t. (97%).

InChI:InChI=1/C10H12O2/c1-7-4-5-10(12-3)9(6-7)8(2)11/h4-6H,1-3H3

Upstream product

• 104-93-8 p-methylanizole 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 
• 1450-72-2 5-methyl-2-hydroxyacetophenone 
• 74-88-4 methyl iodide 
• 64-19-7 acetic acid 
• 76893-86-2 N-methylacetonitrilium trifluoromethanesulphonate 
• 104971-07-5 2-ethynyl-1-methoxy-4-methylbenzene 
• 50597-88-1 2-iodo-4-methylanisole 
• 1548412-52-7 (2-(2-methoxy-5-methylphenyl)ethynyl)trimethylsilane 
• 140-39-6 1-acetoxy-4-methylbenzene 
• 106-44-5 p-cresol 
• 7647-01-0 hydrogenchloride 
• 103095-28-9 1-(2-methoxy-5-methyl-phenyl)-ethanone oxime 

Downstream Products

• 103853-34-5 1-(2-methoxy-5-methyl-phenyl)-ethanone semicarbazone 
• 77915-06-1 (E)-5-Hydroxy-5-(2-methoxy-5-methyl-phenyl)-hex-2-enoic acid 
• 104970-97-0 1-chloro-1-(2-methoxy-5-methylphenyl)ethene 
• 926255-20-1 (S)-1-(2-Methoxy-5-methyl-phenyl)-ethanol 
• 433732-64-0 ethyl E-3-(2-methoxy-5-methylphenyl)but-2-enoate 
• 403519-45-9 E-3-(2-methoxy-5-methylphenyl)but-2-en-1-ol 
• 81784-10-3 1S-(2'-hydroxy-5'-methylphenyl)-1,2,2-trimethylcyclopentane 
• 518014-00-1 6-hydroxy-3-(2-methoxy-5-methyl-phenyl)-3-methyl-hexanoic acid methyl ester 
• 518014-01-2 6-bromo-3-(2-methoxy-5-methyl-phenyl)-3-methyl-hexanoic acid methyl ester 
• 518013-99-5 5-[1,3]dioxolan-2-yl-3-(2-methoxy-5-methyl-phenyl)-3-methyl-pentanoic acid methyl ester 
• 518013-98-4 2-cyano-5-[1,3]dioxolan-2-yl-3-(2-methoxy-5-methyl-phenyl)-3-methyl-pentanoic acid ethyl ester 
• 433732-78-6 4-(2-methoxy-5-methyl-phenyl)-4-methyl-cyclopent-2-enone 
• 433732-75-3 4-(2-methoxy-5-methyl-phenyl)-4-methyl-cyclopent-2-enol 
• 433732-69-5 3-(2-methoxy-5-methyl-phenyl)-3-methyl-pent-4-enal 

Relevant academic research and scientific papers

Facile preparation of 5-alkyl-1-aryltetrazoles with arenes, acyl chlorides, hydroxylamine, and diphenylphosphoryl azide

Successive treatment of arenes with acyl chlorides and AlCl3, the addition of water and removal of solvent, the reaction with NH2OH?HCl and K2CO3, and the reaction with diphenylphosphoryl azide and DBU under warming conditions gave the corresponding 5-alkyl-1-aryltetrazoles efficiently in good to moderate yields. The present method is one-pot transformation of arenes into 5-alkyl-1-aryltetrazoles using the Friedel-Crafts acylation and the Beckmann rearrangement under transition-metal-free conditions.

Iridium-Catalyzed C(sp3)?H Addition of Methyl Ethers across Intramolecular Carbon–Carbon Double Bonds Giving 2,3-Dihydrobenzofurans

Intramolecular addition of an O-methyl C(sp3)?H bond across a carbon-carbon double bond occurs in the iridium-catalyzed reaction of methyl 2-(propen-2-yl)phenyl ethers. The Ir/(S)-DTBM-SEGPHOS catalyst promotes the reaction efficiently in toluene at 110–135 °C to afford 3,3-dimethyl-2,3-dihydrobenzofurans. Enantioselective C(sp3)?H addition is achieved in the reaction of methyl 2-(1-siloxyethenyl)phenyl ethers, affording enantioenriched 3-hydroxy-2,3-dihydrobenzofuran derivatives with up to 96% ee. (Figure presented.).

ROR-GAMMA INHIBITORS

The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.

Synthesis and in vitro activities on anti-platelet aggregation of 4-methoxyisophthalamides

A series of 4-methoxyisophthalamides (1d–1w) were designed and synthesized and their chemical structures were confirmed by IR, MS, 1H-NMR, and 13C-NMR. The in vitro on anti-platelet aggregation activities of these compounds were assessed by using Born method. Compounds with higher activities were selected to continue research via Cell Counting Kit-8 (CCK-8) assays of their cytotoxicities. Biological screening results revealed four compounds 1h, 1i, 1q, and 1v exhibited higher activities than the control drugs on against the platelet aggregation induced by adenosine triphosphate (ADP). Moreover, compounds 1p and 1q exhibited higher in vitro activities than picotamide induced by collagen at the concentration of 1.3 μM. Compound 1p also possessed anti-platelet aggregation activity superior to the control drug picotamide induced by arachidonic acid (AA) at the concentration of 1.3 μM. At the same time, the result of cytotoxicities exhibited that none of the compounds have significant cytotoxicities. Therefore, 4-methoxyisophthalamides are potential to become novel anti-platelet drugs with high activities and minimum toxicities.

New synthesis of 4-methoxyisophthalic acid

A new synthetic route to 4-methoxyisophthalic acid, the key intermediate in the synthesis of Picotamide, is reported. The new protocol starts from commercially available and cheap 4-methylphenol and includes four steps: esterification, Fries rearrangement, methylation, and oxidation; the overall yield is 49%. Unlike the traditional Blanc chloromethylation/oxidation scheme, the proposed procedure avoids using volatile and corrosive hydrochloric acid.

Preparation method for 4-methoxy-1,3-phthalic acid

The invention provides a preparation method for 4-methoxy-1,3-phthalic acid. 4-methoxy-1,3-phthalic acid is key intermediate for preparation of an anti-platelet aggregation drug picotamide (with a trade name of plactidil). According to the preparation method, 4-methoxy-1,3-phthalic acid is prepared from the starting raw material p-methylphenol or o-methylphenol through esterification, Fries rearrangement, methylation, oxidation and acidification. Compared with traditional preparation methods, the preparation method provided by the invention has the advantages of low equipment investment, simple operation, quick reaction, high yield, low synthesis cost, greatly reduced environmental pollution and the like, and is particularly suitable for large-scale industrial production.

New gas-phase domino processes leading to benzopyranones and benzofurans

A new domino approach to flavones by gas phase pyrolysis of β,γ-dioxophosphonium ylides containing a 2-methoxyphenyl group is frustrated by unexpected and novel decarbonylation of the intermediate flavon-3-yl radical leading to 2-phenylbenzofuran. Alternative approaches based on dioxolane protection of one carbonyl, or selective elimination in β,β′-dioxo or β-oxo-β′-thioxo ylides were not successful, but pyrolysis of a β-oxo-β′-phenylimino ylide did give the required domino reaction leading to a protected benzopyranone in moderate yield.

The Stabilized Cation Pool Method: Metal- and Oxidant-Free Benzylic C-H/Aromatic C-H Cross-Coupling

Electrochemical oxidation of toluene derivatives in the presence of a sulfilimine gave benzylaminosulfonium ions as stabilized benzyl cation pools, which reacted with subsequently added aromatic nucleophiles to give the corresponding cross-coupling produc

Reactivity switch enabled by counterion: Highly chemoselective dimerization and hydration of terminal alkynes

A counterion-controlled reactivity tuning in Pd-catalyzed highly chemoselective and regioselective dimerization and hydration of terminal alkynes is reported. The use of acetate as counterion favors the formation of an alkenyl alkynyl palladium intermediate which forms hitherto less reported 1,3-diaryl-substituted conjugated enynes after reductive elimination. Using chloride, which is a better leaving group, leads to anion exchange on the alkenylpalladium intermediate with hydroxide which after reductive elimination and tautomerization delivered the hydration products.

THIAZOLE COMPOUNDS USEFUL AS ACETYL-COA CARBOXYLASE (ACC) INHIBITORS

The present invention provides thiazole compounds of Formula I or its pharmaceutically acceptable salts, prodrugs, solvates, N-oxide thereof; solvates of pharmaceutically acceptable salts and N-oxides; pharmaceutically acceptable salts of N-oxides, or prodrugs; or combination or mixtures thereof; (I) The present invention further provides a method for preventing or treating a condition that responds to an Acetyl-CoA Carboxylase (ACC) inhibitor by using compounds of formula (I) or ), its pharmaceutically acceptable salts, prodrugs, solvates, N-oxide thereof; solvates of pharmaceutically acceptable salts and N-oxides; pharmaceutically acceptable salts of N-oxides, or prodrugs; or combination or mixtures thereof.